Dossier assessment
Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Result of dossier assessment:
Indication of considerable added benefit
Press releases
Darolutamide in prostate cancer: indication of considerable added benefit
Advantages in overall survival, symptoms and health-related quality of life
Project details
- Project no.
- A20-43
- Commission
- Commission awarded on 30.04.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Darolutamide (prostate cancer) - Addendum to Commission A20-43
Status: Commission completed